Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials

[1]  Martin Sill,et al.  Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes , 2019, Acta Neuropathologica.

[2]  Yutaka Suzuki,et al.  Foxr2 promotes formation of CNS-embryonal tumors in a Trp53-deficient background. , 2019, Neuro-oncology.

[3]  T. Merchant,et al.  Molecular Grouping and Outcomes of Young Children with Newly Diagnosed Ependymoma Treated on the Multi-Institutional SJYC07 Trial. , 2019, Neuro-oncology.

[4]  M. Kool,et al.  ETMR-like infantile cerebellar embryonal tumors in the extended morphologic spectrum of DICER1-related tumors , 2018, Acta Neuropathologica.

[5]  J. Finlay,et al.  PDCT-13. PINEOBLASTOMA IN CHILDREN: THE HEAD START EXPERIENCE , 2018, Neuro-Oncology.

[6]  Michael C. Kelly,et al.  Single-cell RNA sequencing of the mammalian pineal gland identifies two pinealocyte subtypes and cell type-specific daily patterns of gene expression , 2018, PloS one.

[7]  David T. W. Jones,et al.  Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Xingxing Xu,et al.  Prognosis of Pediatric Patients with Pineoblastoma: A SEER Analysis 1990-2013. , 2018, World neurosurgery.

[9]  J. Crawford,et al.  Pineoblastoma in a child with 22q11.2 deletion syndrome , 2018, BMJ Case Reports.

[10]  David T. W. Jones,et al.  Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma , 2018, Nature Communications.

[11]  M. Kool,et al.  EMBR-04. WHAT THE FOX SAY? A MOLECULAR ANALYSIS OF FOXR2 IN PEDIATRIC BRAIN TUMORS , 2018, Neuro-Oncology.

[12]  David T. W. Jones,et al.  Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. , 2018, The Lancet. Oncology.

[13]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[14]  G. Qing,et al.  Targeting oncogenic Myc as a strategy for cancer treatment , 2018, Signal Transduction and Targeted Therapy.

[15]  Gretchen M. Williams,et al.  DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies , 2018, Clinical Cancer Research.

[16]  M. de Rademaeker,et al.  Risk of malignancy in 22q11.2 deletion syndrome , 2017, Clinical case reports.

[17]  F. Gilles,et al.  Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data , 2016, Neuro-oncology.

[18]  J. Qin,et al.  FOXR2 Interacts with MYC to Promote Its Transcriptional Activities and Tumorigenesis. , 2016, Cell reports.

[19]  Mei Lu,et al.  Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. , 2016, Cancer cell.

[20]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[21]  Roland Eils,et al.  Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. , 2016, Cancer cell.

[22]  Roland Eils,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[23]  R. Gregory,et al.  MicroRNA biogenesis pathways in cancer , 2015, Nature Reviews Cancer.

[24]  Richard A. Moore,et al.  Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. , 2015, Cancer cell.

[25]  J. Lupski,et al.  Germ-line and somatic DICER1 mutations in pineoblastoma , 2014, Acta Neuropathologica.

[26]  M. Shago,et al.  CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity , 2014, Acta Neuropathologica.

[27]  A. Rust,et al.  Identification of FoxR2 as an oncogene in medulloblastoma. , 2014, Cancer research.

[28]  T. Pietsch,et al.  Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. , 2013, Neuro-oncology.

[29]  W. Foulkes,et al.  Germline DICER1 mutation and associated loss of heterozygosity in a pineoblastoma , 2012, Journal of Medical Genetics.

[30]  J. Mesirov,et al.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Hendrik Witt,et al.  Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Merchant,et al.  A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. , 2009, Neuro-oncology.

[33]  U. Girolami,et al.  Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy , 2008, Journal of Neuro-Oncology.

[34]  Roger E. Taylor,et al.  Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. , 2006, European journal of cancer.

[35]  T. Curran,et al.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Claire L Weston,et al.  beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Mulhern,et al.  Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  V. Kim,et al.  The Drosha-DGCR8 complex in primary microRNA processing. , 2004, Genes & development.

[39]  S. Henriksen,et al.  Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. , 2004, Neuron.

[40]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[41]  R. McLendon,et al.  High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Packer,et al.  Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy , 2000, Cancer.

[43]  T. Kivelä.  Trilateral Retinoblastoma: A Meta-Analysis of Hereditary Retinoblastoma Associated With Primary Ectopic Intracranial Retinoblastoma , 1999 .

[44]  B. Scheithauer,et al.  Pineal parenchymal tumors: Clinical, pathologic, and therapeutic aspects , 1993, Cancer.